Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets (Unaudited)

v3.25.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 12,652 $ 24,125
Inventory 533  
Income taxes receivable 0 48
Prepaid expenses and other current assets 328 614
Total current assets 13,513 24,787
Intangible asset, net 19,404 19,746
Property and equipment, net 18 23
Restricted cash 34 34
Other assets 6 5
Total assets 32,975 44,595
Current liabilities:    
Accounts payable 413 251
Accrued expenses 2,878 2,651
Exchangeable notes 0 14,463
Royalty-linked notes 124  
Income taxes payable 12  
Other current liabilities 201 240
Total current liabilities 3,628 17,605
Pfizer promissory note 20,705 20,300
Royalty-linked notes 11,196 10,771
Total liabilities 35,529 48,676
Commitments and contingencies (Note 16)
Shareholders' deficit    
Undesignated preferred shares, $0.01 par value per share: 100,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued at March 31, 2025 and December 31, 2024
Ordinary shares, $0.01 par value per share: 80,000,000 shares authorized at March 31, 2025 and December 31, 2024, 35,686,616 shares issued at March 31, 2025; 31,534,233 shares issued at December 31, 2024 357 315
Additional Paid in Capital 488,052 481,676
Accumulated deficit (490,963) (486,072)
Accumulated other comprehensive income 0 0
Total shareholders' deficit (2,554) (4,081)
Total liabilities and shareholders' deficit $ 32,975 $ 44,595